i asked COPILOT what % approval by 21st based on accrual of 10 million and here is response: COPILOT's probability estimate: 80–85% This is consistent with:
The company’s own ≥75% internal threshold
The absence of any MHRA “clock stop”
The fact that the review window has already reached the end of the standard 24-month cycle
The company’s decision to publicly take on a $10M liability that disappears if approval is not expected
This is not investment advice — it is a probability assessment based on regulatory process, accounting rules, and observable disclosures.